Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.

Tumors of the middle ear and temporal bone are uncommon, and determining their primary site is often challenging. Due to their proximity to the skull base, nasopharynx, and paranasal sinuses, the ...

Irrfan Khan, known for his acclaimed performances in films such as Life In A Metro, Piku, and The Lunchbox, died on April 29, ...

Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the ...

Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients ...

The field of oncology has seen significant advancements in understanding and treating various types of cancers. One such area ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the ...

Exelixis, Inc. EXEL reported preliminary, unaudited financial results for fiscal year 2025, issued financial guidance for ...

Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data ...

Updated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-tolerated Updated ...

Jason S. Starr, DO, assistant professor of medicine and a hematologist/oncologist in the Department of Internal Medicine at ...